These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25403996)

  • 21. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.
    Dávila-Fajardo CL; Márquez A; Pascual-Salcedo D; Moreno Ramos MJ; García-Portales R; Magro C; Alegre-Sancho JJ; Balsa A; Cabeza-Barrera J; Raya E; Martín J
    Pharmacogenet Genomics; 2014 Jan; 24(1):1-5. PubMed ID: 24253594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies.
    Sarsour K; Greenberg J; Johnston JA; Nelson DR; O'Brien LA; Oddoux C; Ostrer H; Pearlman A; Reed G
    Clin Exp Rheumatol; 2013; 31(2):189-94. PubMed ID: 23294992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders.
    Hession MT; Gottlieb AB
    J Dermatolog Treat; 2011 Apr; 22(2):90-101. PubMed ID: 20673155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.
    Shmidt E; Wetter DA; Ferguson SB; Pittelkow MR
    J Am Acad Dermatol; 2012 Nov; 67(5):e179-85. PubMed ID: 21752492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
    Gisondi P; Cotena C; Tessari G; Girolomoni G
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis.
    Prieto-Pérez R; Solano-López G; Cabaleiro T; Román M; Ochoa D; Talegón M; Baniandrés O; López-Estebaranz JL; de la Cueva P; Daudén E; Abad-Santos F
    Pharmacogenomics J; 2018 Jan; 18(1):70-75. PubMed ID: 27670765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
    Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients.
    Bowes JD; Potter C; Gibbons LJ; Hyrich K; Plant D; Morgan AW; Wilson AG; Isaacs JD; Worthington J; Barton A;
    Pharmacogenet Genomics; 2009 Apr; 19(4):319-23. PubMed ID: 19262425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors.
    Mendrinou E; Patsatsi A; Zafiriou E; Papadopoulou D; Aggelou L; Sarri C; Mamuris Z; Kyriakou A; Sotiriadis D; Roussaki-Schulze A; Sarafidou T; Vasilopoulos Y
    Pharmacogenomics J; 2017 Jun; 17(3):237-241. PubMed ID: 27044681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor necrosis factor-α promoter -308/238 polymorphism association with less severe disease in ankylosing spondylitis is unrelated to serum TNF-α and does not predict TNF inhibitor response.
    Nossent JC; Sagen-Johnsen S; Bakland G
    J Rheumatol; 2014 Aug; 41(8):1675-82. PubMed ID: 25028373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept?
    Murdaca G; Gulli R; Spanò F; Mandich P; Puppo F
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S7-S10. PubMed ID: 25381983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review.
    Grinblat B; Scheinberg M
    Semin Arthritis Rheum; 2008 Feb; 37(4):251-5. PubMed ID: 17640718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
    Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.
    Flendrie M; Vissers WH; Creemers MC; de Jong EM; van de Kerkhof PC; van Riel PL
    Arthritis Res Ther; 2005; 7(3):R666-76. PubMed ID: 15899052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: analysis of 514 patients.
    Dalkilic E; Bulbul Baskan E; Alkis N; Gullulu M; Yavuz M; Dilek K; Ersoy A; Yurtkuran M
    Mod Rheumatol; 2012 Sep; 22(5):738-42. PubMed ID: 22350572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.